“A trio of recent preemption decisions — from the U.S. Supreme Court, the U.S. District Court for the District of New Jersey and the New Jersey Superior Court, Atlantic and Cape May Counties — are good news for pharmaceutical companies facing product liability suits in New Jersey,” writes H. Lockwood (Chip) Miller III, a partner in Goldberg Segalla’s Product Liability and Life Sciences Practice Groups.
In this Law360 Expert Analysis feature, which originally appeared on Goldberg Segalla’s New Jersey Product Liability & Consumer Fraud Defense blog, Chip examines these important rulings and their impact on both brand-name and generic pharmaceutical manufacturers.